<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225406</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 113</org_study_id>
    <nct_id>NCT01225406</nct_id>
  </id_info>
  <brief_title>Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children</brief_title>
  <official_title>Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Security Office, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational cohort study of virologic and immunologic outcome after at least 48
      weeks of third line antiretroviral therapy. Upto 150 children at 8 Thai sites will be
      enrolled. Third line antiretroviral therapy in this study is defined as an antiretroviral
      (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy
      and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as
      darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will
      help the Thai government in planning its strategy to provide third line ARV therapy to
      children within the national program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the virological efficacy, as measured by the
      proportions of children with HIV RNA below 400 and 50 copies/ml at 48 weeks after initiating
      third line ARV therapy.

      Third line ARV therapy is defined as an ARV regimen in a patient who has failure or
      intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens
      may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and
      raltegravir
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>undetectable viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>Primary endpoint will be the proportions of subjects with HIV RNA below 400 and 50 copies/ml at 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of subjects with hyperlipidemia as a measure of safety</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy</condition>
  <arm_group>
    <arm_group_label>third line naive</arm_group_label>
    <description>Children on second line or other regimen who switch or start third line regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>third line experienced</arm_group_label>
    <description>children who are on third line regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <arm_group_label>third line naive</arm_group_label>
    <arm_group_label>third line experienced</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and PBMC
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Thai children aged &lt; 18 years old who are on or are switching to third line antiretroviral
        therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Children (&lt; 18 years old) with HIV infection may enroll if one of the following criteria is
        met:

          1. Have resistance to at least one drug in each of the 3 classes (NRTI, NNRTI and PI) and
             have plasma HIV RNA &gt; 1000 copies/ml prior to switching to third line ARV therapy

          2. Have intolerance to the current NRTI, NNRTI or PI treatment and need to receive
             darunavir, etravirine, tipranavir or raltegravir

        Exclusion Criteria:

          1. Have hepatic impairment with ALT ≥ 5 upper limit of normal

          2. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanyawee Puthanakit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University, Bangkok</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kulkanya Chokephaibulkit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siriraj Hospital, Mahidol University, Bangkok, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV-NAT</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Chantaburi</name>
      <address>
        <city>Chantaburi</city>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Rai Regional Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surin Hospital</name>
      <address>
        <city>Surin</city>
        <zip>32000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Chokephaibulkit K, Prasitsuebsai W, Wittawatmongkol O, Gorowara M, Phongsamart W, Sophonphan J, Kerr SJ, Vanprapar N, Puthanakit T, Pasomsap C, Suwanlerk T, Sekar V, Burger D, Ananworanich J; HIV-NAT 113 Pharmacokinetic Study Group. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years. Antivir Ther. 2012;17(7):1263-9. doi: 10.3851/IMP2347. Epub 2012 Sep 6.</citation>
    <PMID>22954687</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Third line ARV therapy</keyword>
  <keyword>HIV RNA</keyword>
  <keyword>Absolute CD4+ T cell count</keyword>
  <keyword>serious adverse events (SAEs)</keyword>
  <keyword>Drug resistance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

